4DMT has sold the Asia-Pacific…
4DMT has sold the Asia-Pacific rights to its eye gene [...]
Gilead has chosen a partner for…
Gilead has chosen a partner for lenacapavir in the race [...]
Steven Hatfill, a senior advisor…
Steven Hatfill, a senior advisor for biosecurity at the Department [...]
Eli Lilly has halted development…
Eli Lilly has halted development of a phase 2 P2X7 [...]
Bristol Myers Squibb is shedding…
Bristol Myers Squibb is shedding two clinical programs from its [...]
Inflammation biotech Evommune…
Inflammation biotech Evommune plans to take the leap into public [...]
Sensei Biotherapeutics is…
Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning [...]
Takeda has given up on an…
Takeda has given up on an AstraZeneca-partnered neurological disorder program [...]
Roche’s Genentech unit is laying…
Roche’s Genentech unit is laying off staff at its Bay [...]
AbbVie has scrapped an asset from…
AbbVie has scrapped an asset from its ongoing collaboration with [...]